meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
antibody–drug conjugate
trastuzumab deruxtecan
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab alone
Ipilimumab (10 mg/kg)
anti-PD-(L)1
avelumab based treatment
avelumab alone
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
no study with result for this clinical condition